Aqualung Therapeutics Corp.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2010-01-01
- Employees
- 1
- Market Cap
- -
Clinical Trials
2
Active:1
Completed:1
Trial Phases
2 Phases
Phase 1:1
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (50.0%)Phase 2
1 (50.0%)Study of Safety and Efficacy of ALT-100mAb in Participants With Moderate/Severe ARDS
Phase 2
Active, not recruiting
- Conditions
- Acute Respiratory Distress Syndrome (ARDS)
- Interventions
- Drug: ALT-100 mAbDrug: ALT-100 (Placebo)
- First Posted Date
- 2023-07-10
- Last Posted Date
- 2025-10-23
- Lead Sponsor
- Aqualung Therapeutics Corp.
- Target Recruit Count
- 15
- Registration Number
- NCT05938036
- Locations
- 🇺🇸
Banner University of Arizona, Tucson, Arizona, United States
First-In-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ALT-100
- First Posted Date
- 2022-06-22
- Last Posted Date
- 2023-09-14
- Lead Sponsor
- Aqualung Therapeutics Corp.
- Target Recruit Count
- 32
- Registration Number
- NCT05426746
- Locations
- 🇦🇺
CMAX Clinical Research Pty Ltd, Adelaide, South Australia, Australia
News
No news found